UMI - Re Novavax COVID-19 vaccine

The Novavax COVID-19 vaccine has not been approved or licensed by the U.S. Food and Drug Administration (FDA), but has been authorized for emergency use as a primary series to prevent COVID-19 in individuals 12+

Per Novavax “ Novavax COVID-19 Vaccine, Adjuvanted contains a version of the SARS-CoV-2 spike protein that has been designed in a lab. its COVID-19 Vaccine, Adjuvanted contains a recombinant form of the SARS-CoV-2 spike protein produced from baculovirus infected Sf9 (fall armyworm insect cells and Matrix-MTM adjuvant containing saponins derived from the soapbark tree (Quillaja saponaria Molina). Other ingredients include cholesterol, phosphatidylcholine, potassium dihydrogen phosphate, potassium chloride, disodium hydrogen phosphate dihydrate, sodium chloride, disodium hydrogen phosphate heptahydrate, sodium dihydrogen phosphate monohydrate, polysorbate 80, and water for injection. The vaccine may also contain small amounts of baculovirus and insect cell proteins and DNA.” https://novavax.widen.net/s/9nlr2nw8gx/novavax-covid-19-vaccine-adjuvanted-frequently-asked-questions